407 related articles for article (PubMed ID: 19008049)
21. HER2-positive breast cancer: beyond trastuzumab.
Murphy CG; Fornier M
Oncology (Williston Park); 2010 Apr; 24(5):410-5. PubMed ID: 20480738
[TBL] [Abstract][Full Text] [Related]
22. Lapatinib in breast cancer: clinical experiences and future perspectives.
Giampaglia M; Chiuri VE; Tinelli A; De Laurentiis M; Silvestris N; Lorusso V
Cancer Treat Rev; 2010 Nov; 36 Suppl 3():S72-9. PubMed ID: 21129615
[TBL] [Abstract][Full Text] [Related]
23. Enhancing the efficacy of hormonal agents with selected targeted agents.
Johnston SR
Clin Breast Cancer; 2009 Jun; 9 Suppl 1():S28-36. PubMed ID: 19561004
[TBL] [Abstract][Full Text] [Related]
24. Lapatinib.
Schneider-Merck T; Trepel M
Recent Results Cancer Res; 2010; 184():45-59. PubMed ID: 20072830
[TBL] [Abstract][Full Text] [Related]
25. Lapatinib.
Voigtlaender M; Schneider-Merck T; Trepel M
Recent Results Cancer Res; 2018; 211():19-44. PubMed ID: 30069757
[TBL] [Abstract][Full Text] [Related]
26. Recent advances in novel targeted therapies for HER2-positive breast cancer.
Murphy CG; Morris PG
Anticancer Drugs; 2012 Sep; 23(8):765-76. PubMed ID: 22824822
[TBL] [Abstract][Full Text] [Related]
27. Management of patients with HER2-positive metastatic breast cancer: is there an optimal sequence of HER2-directed approaches?
Zelnak AB; Wisinski KB
Cancer; 2015 Jan; 121(1):17-24. PubMed ID: 25056442
[TBL] [Abstract][Full Text] [Related]
28. Closing remarks and treatment guidelines.
Piccart M
Eur J Cancer; 2001 Jan; 37 Suppl 1():S30-3. PubMed ID: 11167089
[TBL] [Abstract][Full Text] [Related]
29. EGFR targeting therapies: monoclonal antibodies versus tyrosine kinase inhibitors. Similarities and differences.
Dassonville O; Bozec A; Fischel JL; Milano G
Crit Rev Oncol Hematol; 2007 Apr; 62(1):53-61. PubMed ID: 17324578
[TBL] [Abstract][Full Text] [Related]
30. Anthracycline- and/or taxane-resistant breast cancer: results of a literature review to determine the clinical challenges and current treatment trends.
Moreno-Aspitia A; Perez EA
Clin Ther; 2009 Aug; 31(8):1619-40. PubMed ID: 19808124
[TBL] [Abstract][Full Text] [Related]
31. Management of metastatic HER2-positive breast cancer progression after adjuvant trastuzumab therapy - current evidence and future trends.
Metzger-Filho O; Vora T; Awada A
Expert Opin Investig Drugs; 2010 Apr; 19 Suppl 1():S31-9. PubMed ID: 20374028
[TBL] [Abstract][Full Text] [Related]
32. HER-2 gene amplification, HER-2 and epidermal growth factor receptor mRNA and protein expression, and lapatinib efficacy in women with metastatic breast cancer.
Press MF; Finn RS; Cameron D; Di Leo A; Geyer CE; Villalobos IE; Santiago A; Guzman R; Gasparyan A; Ma Y; Danenberg K; Martin AM; Williams L; Oliva C; Stein S; Gagnon R; Arbushites M; Koehler MT
Clin Cancer Res; 2008 Dec; 14(23):7861-70. PubMed ID: 19047115
[TBL] [Abstract][Full Text] [Related]
33. The growth inhibitory effect of lapatinib, a dual inhibitor of EGFR and HER2 tyrosine kinase, in gastric cancer cell lines.
Kim JW; Kim HP; Im SA; Kang S; Hur HS; Yoon YK; Oh DY; Kim JH; Lee DS; Kim TY; Bang YJ
Cancer Lett; 2008 Dec; 272(2):296-306. PubMed ID: 18774637
[TBL] [Abstract][Full Text] [Related]
34. HER2-positive breast cancer: from trastuzumab to innovatory anti-HER2 strategies.
Whenham N; D'Hondt V; Piccart MJ
Clin Breast Cancer; 2008 Feb; 8(1):38-49. PubMed ID: 18501058
[TBL] [Abstract][Full Text] [Related]
35. Revoking the privilege: targeting HER2 in the central nervous system.
Contessa JN; Hamstra DA
Mol Pharmacol; 2008 Feb; 73(2):271-3. PubMed ID: 17981994
[TBL] [Abstract][Full Text] [Related]
36. [Will targeted therapies replace chemotherapy?].
Collignon J; Jerusalem G
Rev Med Liege; 2012; 67 Spec No():29-36. PubMed ID: 22690483
[TBL] [Abstract][Full Text] [Related]
37. Integration of novel targeted therapies into the systemic treatment of breast cancer--a review.
Tsakonas G; Kosmas C
J BUON; 2007; 12(3):319-27. PubMed ID: 17918284
[TBL] [Abstract][Full Text] [Related]
38. Lapatinib-associated toxicity and practical management recommendations.
Moy B; Goss PE
Oncologist; 2007 Jul; 12(7):756-65. PubMed ID: 17673607
[TBL] [Abstract][Full Text] [Related]
39. Advances in targeting human epidermal growth factor receptor-2 signaling for cancer therapy.
Meric-Bernstam F; Hung MC
Clin Cancer Res; 2006 Nov; 12(21):6326-30. PubMed ID: 17085641
[TBL] [Abstract][Full Text] [Related]
40. Epidermal growth factor receptor inhibition strategies in pancreatic cancer: past, present and the future.
Cohenuram M; Saif MW
JOP; 2007 Jan; 8(1):4-15. PubMed ID: 17228128
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
